CHAPTER 7

BIBLIOGRAPHY
7.0 BIBLIOGRAPHY


283


Bibliography


123 Hert MD et al. (2009) Metabolic syndrome in people with schizophrenia a review World Psychiatry 8(1).pp.15-22


289
132 Huang MW, Yang Tsung-Tsair, Ten Po-Ren, Su Po-Wen, Wu Bo-Jian, Chan Chin-Hong et al. (2012) *BMC Clinical Pharmacology*. 12:1


291


182. Lahon K, Shetty HM, Paramel A, Sharma G. (2012 Jul-Sep) A retrospective study of extrapyramidal syndromes with second generation antipsychotics in the psychiatric unit of a tertiary care teaching hospital J Pharmacol Pharmcother. 3(3). pp 266-8


187 Laruelle M, Abi-Dargham A (1999a) Dopamine as the wind of the psychotic fire: New evidence from brain imaging studies Journal of Psychopharmacology, 13, pp 358-71


217 McDonagh MS, Peterson K, Carson S, Fu R, Thakurta S (July 2010). Drug Class Review: Atypical Antipsychotic Drugs Update 3. USA. Oregon Health & Science University.


231 Miyamoto S, Duncan GE, Marx CE and Lieberman JA. (2005) Treatments for schizophrenia: a critical review of pharmacology and mechanisms of action of antipsychotic drugs Molecular Psychiatry 10, pp. 79-104


244. Naber D & Karow A. (2001) Good tolerability equals good results the patient’s perspective Eur Neuropsychopharmacol 11 (4) S391-6 (abstract)


265. Reed PG (2010) Let’s target Screening more effectively *The Psychiatrist Online* 34:pp.540-1


Bibliography
Bibliography


334 Walid, S. (April 2010), The Metabolic Syndrome in Patients Treated with Atypical Neuroleptics. First International Congress of the Jordanian Association of Psychiatrists, Amman-Jordan


343 World Health Organization. (1992) The ICD-10 Classification of Mental and Behavioural Disorders: Clinical Descriptions and Diagnostic Guidelines. WHO


